| Over a month ago | ||||
Needham analyst James… Needham analyst James Ricchiuti raised his price target on Plexus to $88 and kept his Buy rating after Q1 earnings beat and 11% growth in revenue that exceeded the guided 2%-7%. The analyst notes that the beat was driven by the pull-ins of business in the health care life science vertical and much stronger-than-expected growth in the Industrial and Commercial markets. Ricchiuti adds that while the management anticipates flat revenue growth in Q2, the company also sees better opportunities in the second half of FY20 with potentially improved demand in the semi-cap sector. | ||||
Plexus CEO Todd Kelsey… Plexus CEO Todd Kelsey said, "Our outlook for fiscal 2020 remains generally unchanged from previous expectations as we anticipate sequentially increasing revenue during the second half of the fiscal year. Coupling this with our largely stable end-markets, a talented work force focused on delighting our customers, and our comprehensive service offerings, we anticipate solid operating performance with a return to operating margin within our target range of 4.7%-5.0%. This would lead to robust EPS expansion for the fiscal year." | ||||
For the three months… For the three months ended January 4, 2020, cash flows provided by operations was $74.7M, less capital expenditures of $13.7M, resulting in free cash flow of $61.0M. | ||||
Sees Q2 revenue… Sees Q2 revenue $790M-$830M, consensus $821.36M. | ||||
Reports Q1 revenue $852M,… Reports Q1 revenue $852M, consensus $803.38M. | ||||
| Over a quarter ago | ||||
In a regulatory filing,… In a regulatory filing, Plexus disclosed that its chairman Dean Foate sold 8K shares of common stock on November 21st. The total transaction size was $615K. | ||||
Meetings to be held in… Meetings to be held in Ohio on November 20 and in New York on November 21 hosted by Sidoti. | ||||
Meetings to be held in… Meetings to be held in Ohio on November 20 and in New York on November 21 hosted by Sidoti. | ||||
In a regulatory filing,… In a regulatory filing, Plexus's Yong Jin Lim, regional president of the company's Asia Pacific division, disclosed the sale of 15,000 common shares of the company at a price of $72.1518 per share. | ||||
As previously reported,… As previously reported, Sidoti analyst Anja Soderstrom downgraded Plexus to Neutral from Buy with an unchanged $72 price target. The stock is is up 22% in the past 12 months and up 9% since reporting Q4 results, noted the analyst, who lowered estimates for FY20 growth to 6% from 8% and cut the FY21 revenue growth projection to 10% from 11%. | ||||